Home › New Data from IMPROVE-IT Study of VYTORIN (ezetimibe/simvastatin) and TRA 2P TIMI 50 Study of ZONTIVITY (vorapaxar) to be Presented at American College of Cardiology Scientific Sessions
 

Keywords :   


New Data from IMPROVE-IT Study of VYTORIN (ezetimibe/simvastatin) and TRA 2P TIMI 50 Study of ZONTIVITY (vorapaxar) to be Presented at American College of Cardiology Scientific Sessions

2015-02-25 14:00:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. Investigational data from IMPROVE-IT to be announced in Featured Clinical Research Session II KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that new data from two trials of the companys cardiovascular medicines will be presented at the 2015 American College of Cardiology Annual Scientific Sessions (ACC.15), March 14-16 in San Diego. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orMichael Close, 267-305-1211orInvestor:Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: of data american study

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
18.05Eastern North Pacific Tropical Weather Outlook
18.05Atlantic Tropical Weather Outlook
18.05Producers to be paid grid premiums for AngusLink beef scores
18.05This Week in Agribusiness, May 18, 2024
18.05This Week in Agribusiness, May 18, 2024
18.05Unpaid carers being forced to repay 250m to DWP
18.05Weekly Recap: Hempel, Axalta, KANSAI HELIOS Top This Weeks Stories
18.05Eastern North Pacific Tropical Weather Outlook
More »